Market News & Trends
Apellis & Sobi Enter Collaboration for Global Co-Development & Ex-US Commercialization of Systemic Pegcetacoplan
Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB recently announced a strategic collaboration to accelerate the advancement of systemic pegcetacoplan, a targeted….
Catalent to Acquire Cell Therapy Manufacturing Facility From Bone Therapeutics
Catalent recently announced it had signed an agreement with Bone Therapeutics to acquire its cell therapy manufacturing subsidiary, Skeletal Cell Therapy Support SA (SCTS), including…
XOMA Earns $25-Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 2 Clinical Study
XOMA Corporation recently announced NIS793, an anti-TGFβ monoclonal antibody licensed from XOMA, has advanced to the Phase 2 development stage, triggering a $25-million milestone payment…
Taconic Biosciences Launches Critical Model for COVID-19 Research
Taconic Biosciences recently announced immediate humanized ACE2 mouse model availability for COVID-19 research. The SARS-CoV-2 virus, which causes COVID-19, uses the ACE2 receptor to enter…
Orasis Pharmaceuticals Announces Initiation of Phase 3 Clinical Studies of Novel Eye Drop Candidate
Orasis Pharmaceuticals recently announced the initiation of NEAR-1 and NEAR-2 Phase 3 clinical studies in the US, evaluating its novel eye drop candidate designed to…
Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update
Novavax, Inc. recently announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19 vaccine candidate. NVX‑CoV2373 is a stable, prefusion protein made…
miRagen Therapeutics Announces Acquisition of Viridian Therapeutics
miRagen Therapeutics, Inc. recently announced it has completed the acquisition of Viridian Therapeutics, Inc., a privately held biotechnology company focused on advancing new treatments for…
Evonik Launches Ready-to-Use Powder Premix to Improve Processing, Appearance & Swallowability of Oral Drug Products With an Immediate-Release Profile
Evonik recently launched a new ready-to-use powder premix blend of its EUDRAGIT functional polymers used for oral products with an immediate-release profile. EUDRAGIT IR ReadyMix…
Bayer Acquires Company to Broaden Innovation Base in Cell & Gene Therapy
Bayer AG recently announced the acquisition of Asklepios BioPharmaceutical, Inc., a US-headquartered biopharmaceutical company specialized in the research, development, and manufacturing of gene therapies across different therapeutic areas…..
Lonza Significantly Expands Its Capsule Manufacturing Capacity
Lonza recently announced a $93-million investment in its Capsules and Health Ingredients (CHI) Division, a dosage form delivery partner to the biopharma and health nutrition industry…..
Quantum Genomics Enters Exclusive Licensing & Collaboration Agreement With Qilu Pharmaceutical
Quantum Genomics recently announced it has entered into an exclusive licensing and collaboration agreement with Qilu Pharmaceutical to develop and commercialize….
NGM Expands Oncology Portfolio With First Immuno-Oncology Development Candidate
NGM Biopharmaceuticals, Inc. recently announced the expansion of its oncology portfolio with its first immuno-oncology development candidate….
Catalent Launches Delayed/Enteric-Release Softgel for Pharmaceutical & Nutraceutical Applications
Catalent recently announced the launch of OptiGel DR technology for the formulation and manufacture of delayed/enteric-release softgels. The technology allows softgel capsules to be formed…
BrainStorm Cell Therapeutics & Catalent Announce Manufacturing Partnership
Catalent and BrainStorm Cell Therapeutics Inc. recently announced an agreement for the manufacture of NurOwn, BrainStorm’s autologous cellular therapy being investigated for the treatment of….
VBL Therapeutics Announces Additional New European Patent
VBL Therapeutics recently announced the European Patent Office (EPO) has granted Patent No. 3328401, which covers VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat oncology…
First Patient Dosed in Phase 2 Trial to Treat Complications in COVID-19
Arch Biopartners Inc. recently announced it has dosed the first patient in the Phase 2 trial of its lead drug LSALT peptide, targeting prevention of…
PepTC Vaccines Publishes Positive Preclinical Results for COVID-19 Peptide Vaccine
PepTC Vaccines Limited, a subsidiary of Treos Bio Limited, recently announced the publication of positive preclinical results of its investigational PolyPEPI-SCoV-2 peptide vaccine. The study…
Castle Creek Biosciences Treats First Patient in Phase 1/2 Gene Therapy Trial
Castle Creek Biosciences, Inc. recently announced that the first adult patient has been dosed in a Phase 1/2 clinical trial evaluating FCX-013, the company’s investigational…
Beroni Group Announces Successful Completion of SARS-CoV-2 Pseudovirus Neutralization Assay for Treatment of COVID-19
Beroni Group recently announced successful completion of SARS-CoV-2 pseudovirus neutralization assay in collaboration with GenScript Biotech Corporation (HKSE:1548), a leading global biotechnology company. The assay…
Aptose Initiates Dosing of CG-806 in Patients With Acute Myeloid Leukemia
Aptose Biosciences Inc. recently announced dosing of the first patient with acute myeloid leukemia (AML) in a Phase 1 a/b clinical study with CG-806, the…
